Figure 4.
Kaplan-Meier estimates of time from EOT to MRD conversion (A) and time from MRD* conversion to PD† (B) in VenR-treated patients (n = 83) who had uMRD at EOT. *MRD conversion was defined as 2 consecutive assays detecting MRD at ≥10−4 or PD according to iwCLL criteria31 in patients who previously had uMRD. †Investigators assessed PD by using iwCLL criteria.31 uMRD, <1 CLL cell/10 000 leukocytes. +, censored.

Kaplan-Meier estimates of time from EOT to MRD conversion (A) and time from MRD* conversion to PD† (B) in VenR-treated patients (n = 83) who had uMRD at EOT. *MRD conversion was defined as 2 consecutive assays detecting MRD at ≥10−4 or PD according to iwCLL criteria31 in patients who previously had uMRD. †Investigators assessed PD by using iwCLL criteria.31 uMRD, <1 CLL cell/10 000 leukocytes. +, censored.

Close Modal

or Create an Account

Close Modal
Close Modal